Signios Biosciences and Illumina, Inc. announced on May 19, 2025, an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. This grant aims to maximize discovery power with the industry's largest next-generation sequencing (NGS)-based proteomics panel.
The Illumina Protein Prep 9.5K™ platform, powered by SOMAmer® technology, enables comprehensive proteomic profiling of plasma and serum by selectively binding approximately 9,500 unique human protein targets. Quantification is performed on the NovaSeq™ sequencing system.
A panel of experts from Signios Bio and Illumina will select a grant winner, covering the cost of proteomic profiling for up to 170 samples. This initiative is designed to support data analysis and publication efforts using the Illumina Connected Multiomics platform, fostering broader adoption and research with this advanced proteomics solution.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.